Introduction
============

Artificial intelligence (AI) has recently experienced an era of explosive growth across many industries, and healthcare is no exception [@B1]. AI will have particular utility in healthcare and will dramatically change the diagnostic and treatment pathways for many, if not most, diseases. Regardless of the specific technique, the general aim of these technologies in medicine is to use computer algorithms to uncover relevant information from data and to assist clinical decision making [@B2]. In many developed countries and China, the application of AI technology in healthcare has developed quickly, at least in part because it enhances human resources and abilities and improves the accuracy of medical treatment. As many countries that support the development of advanced technologies welcome the incoming era of AI, they will begin to develop the necessary specifications of governance by law, regulation, technology, and standards to fully optimize this developing field of technology.

Ophthalmology is a discipline that is highly dependent on technological development. Modern ophthalmology currently makes full use of mechanical, electrical, magnetic, acoustic, optical, and other imaging technologies, and it will lead in fully implementing and adapting new technological developments such as AI. Ophthalmologists should enthusiastically embrace the development of AI technology and use it to promote advances in ocular medicine as much as possible.

Workflow of deep learning
=========================

AI is broadly used in both the technical and popular lexicons to encompass a spectrum of learning, including but not limited to machine learning, representation learning, deep learning, and natural language processing [@B1]. Deep learning is making major advances in solving problems that have resisted the best attempts of the AI community for many years. It is very good at discovering intricate structures in high-dimensional data and is therefore applicable to multiple medical domains [@B3]. Deep learning discovers intricate structure in large data sets by using multiple intermediate layers positioned between the input and output layers, allowing each level to learn to transform its input signal into the following layer (Fig [1](#F1){ref-type="fig"}). The application of deep learning, particularly in images of the retina include classification, e.g., detection of diabetic retinopathy (DR) and diabetic macular edema (DME) in fundus photographs [@B4]; segmentation, e.g., segmentation of the lungs [@B5], brain [@B6], cell mitosis [@B7]; and prediction, e.g., prediction of myopia development and progression [@B8]. The workflow of deep learning can be defined in three stages: (1) pre-processing of the image data; (2) training of the model, validation, and model testing; and (3) evaluation (Fig. [2](#F2){ref-type="fig"}). Data pre-processing is a critical step that is necessary to build accurate machine learning models. The pre-processed work includes noise reduction, data normalization, feature selection, and extraction [@B9]. For training a model, we initially split the model into three sections: data training, validation, and testing. The training set enables the model to learn to fit the data parameters of the classifier. The validation set is used to prevent overfitting, and the test set is used to evaluate the performance of the trained model. Evaluation is an integral part of the development process. It helps to determine if the model will do a good job of predicting the target on new and future data.

Common open database of retina images
=====================================

Many public databases have been published, and most include instructions for use by researchers in analysis and testing. For diseases of the retina, the databases include basic pathological features that usually provide information about the seven layers of the retina and about the choroid and sclera. This type of information is compiled by a process referred to as "segmentation", which historically has been achieved by manual image processing, but increasingly it is done by computer algorithms. This information allows comparison of the performance of different algorithms analyzing the same fundus image, with reference to the reliable implementation of a gold-standard procedure [@B10]. Commonly used fundus databases includes DRIVE [@B11], STARE [@B12], Image-Ret [@B13],[@B14], e-ophtha [@B15], HEI-MED [@B16], Retinopathy Online Challenge [@B17], Messidor [@B18], RIM-ONE [@B19], and DRION-DB [@B20]. Among them, DRIVE, STARE, Image-Ret, and Messidor are used mostly to diagnose DR, while DRION-DB and RIM-ONE are used mostly for segmentation of the optic nerve head in the diagnosis of glaucoma (Table [1](#T1){ref-type="table"}).

Important research studies applying artificial intelligence to ophthalmic conditions
====================================================================================

Image classification is a long-term research topic in the field of computer vision and pattern recognition. Recent advances of deep learning techniques have greatly facilitated the research of image classification. Many deep learning models have demonstrated performances comparable with well-trained human experts in the classification of natural images, and some have outperformed the experts. The flourish of deep learning-based image classification started with the work of AlexNet [@B21], where an eight-layered convolutional neural network (CNN) was designed for the classification task in ImageNet Large Scale Visual Recognition Challenge (ILSVRC). Subsequently, a series of deeper neural networks continuously refreshed the record of ILSVRC, including GoogLeNet (22 layers) [@B22], VGGNet (16 or 19 layers) [@B23], and Deep Residual Net (18, 34, 50, 101, or 152 layers) [@B24]. These neural networks are the most widely used architectures that can achieve accurate classification for natural images by training deep models with millions of annotated images.

Diabetic retinopathy
====================

Diabetic retinopathy is the most common organ complication and can manifest as the earliest sign of complication of diabetes mellitus. Early detection and continuous monitoring of DR is essential to control the disease in the early stage to prevent blindness. The automatic detection of DR has attracted a lot of attention. Most automated methods use fundus images as an input. These photographs are examined for the presence of lesions indicative of DR, including microaneurysms, hemorrhages, exudates, and cotton wool spots. The application of automated image analysis to fundus images may reduce the workload and costs by minimizing the number of photographs that need to be manually graded [@B25]. Gulshan et al [@B4] were the first to present a deep learning algorithm for the detection of DR in retinal fundus photographs. In 2 validation sets of 9963 images and 1748 images, at the operating point selected for high specificity, the algorithm had 90.3%and 87.0%sensitivity and 98.1%and 98.5%specificity for detecting referable diabetic retinopathy, defined as moderate or worse diabetic retinopathy or referable macular edema by the majority decision of a panel of at least 7 US board-certified ophthalmologists. Subsequently, Ting et al[@B26] developed a deep learning system to detect multiple related eye diseases, including DR, possible glaucoma, and age-related macular degeneration(AMD), the Area under the receiver operating characteristic curve (AUC) of 0.936 for referable DR ,sensitivity and specificity were 90.5% and 91.6%, For vision-threatening diabetic retinopathy, AUC was 0.958,sensitivity and specificity were 100% and 91.1%. More recently, deep learning was applied to automated segmentation of optical coherence tomography (OCT) images. Kermany et al [@B27] developed an OCT imaging diagnostic tool based on a deep learning framework for screening patients with AMD, DME, and drusen. The classifier distinguishing DME images from normal images achieved an accuracy of 98.2%, with a sensitivity of 96.8% and specificity of 99.6%. In April 2018, the first AI diagnostic system to receive US Food and Drug Administration (FDA) approval for marketing was IDx-DR, the case of IDx-DR highlights one of the earliest successes of an AI-based technology completing the regulatory process in the United States.

Glaucoma
========

Glaucoma is a group of eye diseases that damage the optic nerve and can result in irreversible vision loss and blindness and is the second leading cause of blindness worldwide. It is estimated that the disease affected 60.5 million people in 2010, and this figure is expected to reach 79.6 million by 2020 [@B28]. Currently, there is no cure for glaucoma, and vision loss, once it has occurred, is permanent. However, early detection and treatment are helpful to slow or stop the disease progression and can protect against serious vision loss. Many researchers have studied how to diagnose glaucoma automatically based on retinal images. These studies can be separated into two types. The first type outputs the glaucoma diagnosis results directly through deep learning models. Li et al [@B29] trained a CNN on LabelMe datasets for glaucoma diagnosis, In the validation dataset, this DL system achieved an AUC of 0.986 with sensitivity of 95.6% and specificity of 92.0%. The most common reasons for false-negative grading were glaucomatous optic neuropathy with coexisting eye conditions, including pathologic or high myopia, DR, and AMD. The leading reason for false-positive results was having other eye conditions, mainly including physiologic cupping. The second type of studies uses deep learning models to segment the glaucoma related tissues such as optic disc and optic cup, and then calculates medical measures (e.g., cup-to-disc ratio) for diagnosis. Previous studies have used various special forms of perimetry to discriminate preperimetric glaucoma from healthy eyes[@B30]. Asaoka et al [@B31] applied a DL method to differentiate the visual fields of preperimetric open-angle glaucoma patients from the healthy eyes, the AUC was 0.926.

Age-Related Macular Degeneration
================================

AMD is a leading cause of irreversible visual loss in the aging population; the meta-analysis conducted by Wong et al [@B32] suggested that AMD, was responsible for 8.7% of all global blindness. Fortunately, the anti-vascular endothelial growth factor (anti-VEGF) medications have revolutionized the treatment of exudative retinal diseases, OCT is critical to guiding the administration of anti-VEGF therapy by providing a clear cross-sectional representation of the retinal pathology in these conditions. Kermany et al [@B27] developed an OCT imaging diagnostic tool based on a deep learning framework for screening patients with AMD, DME, and drusen. This AI system categorized images with choroidal neovascularization and images with diabetic macular edema as "urgent referrals", drusen as "routine referrals", normal images were labeled for "observation". They achieved an accuracy of 96.6%, with a sensitivity of 97.8%, a specificity of 97.4%, and a weighted error of 6.6%. The classifier distinguishing choroidal neovascularization images from normal images achieved an accuracy of 100.0%, with a sensitivity of 100.0% and specificity of 100.0%. Recently, DeepMind and the Moorfields Eye Hospital [@B33] developed an AI system was trained on 14 884 OCT scans to detect 9 different OCT pathologies (choroidal neovascularization, macular edema, drusen, geographic atrophy, epiretinal membrane, vitreomacular traction, full-thickness macular hole, partial thickness macular hole, and central serous retinopathy). The system was then able to recommend a referral decision based on the most urgent conditions detected, the correct referral decision with 94% accuracy, matching world-leading eye experts.

In addition to detecting and monitoring common blinding eye diseases, deep learning is also being expanded to the field of rare diseases, such as congenital cataracts and retinopathy of prematurity (ROP) in newborns. Long et al [@B34] constructed a CNN-based computer-aided diagnosis framework (CC-Cruiser) to classify and grade congenital cataract. In the clinical trial, CC-Cruiser achieved 98.25% accuracy with the identification networks; 100%, 92.86% and 100% accuracy for opacity areas, densities and locations, respectively, with the evaluation networks; and 92.86% accuracy with the strategist networks. Brown et al [@B35] reported the results of a fully automated DL system that could diagnose plus disease, the most important feature of severe ROP, for diagnosis of plus disease, the algorithm achieved a sensitivity of 93% with 94% specificity. For detection of pre-plus disease or worse, the sensitivity and specificity were 100% and 94%, respectively. In addition, retinal microvascular changes and retinopathy provide important clinical indicators for predicting the occurrence, development, therapeutic effect and prognosis of cardiovascular and cerebrovascular diseases. Poplin et al[@B36] using deep-learning models trained on data from 284,335 patients and validated on two independent datasets of 12,026 and 999 patients, they predicted cardiovascular risk factors not previously thought to be present or quantifiable in retinal images, such as age (mean absolute error within 3.26 years), gender(AUC) = 0.97, smoking status (AUC = 0.71), systolic blood pressure (mean absolute error within 11.23 mmHg) and major adverse cardiac events (AUC = 0.70).Current AI studies using deep learning techniques for DR, AMD, glaucoma, cataract, and anterior ocular segment diseases are summarized in Table [2](#T2){ref-type="table"} [@B4],[@B26],[@B27],[@B29],[@B31],[@B34],[@B37]-[@B63].

Status of AI applications in clinical diagnoses
===============================================

On April 2, 2019, the FDA issued a discussion paper that proposed a regulatory framework for modifications to artificial intelligence/machine learning (AI/ML)-based software as medical devices (SaMD) [@B64]. This document explains the principles for developing artificial intelligence software, the new framework for equipment, the principles of the total product lifecycle (TPLC) certification methodology, and examples of potential real-world AI software modifications that may or may not be allowed under the proposed framework. The idea of the proposal was that with appropriately tailored regulatory oversight, AI/ML-based SaMD will deliver safe and effective software functionality that improves the quality of care that patients receive.

To date, two AI algorithms have been fully approved by the FDA and used clinically. One is IDx-DR for detecting DR, and the other is Viz.AI for analyzing images for indicators associated with a stroke. These two devices are described as "locked" algorithms, meaning that they can only be modified by the manufacturer at intervals for the purpose of "training" with new data, followed by manual verification and validation of the updated algorithm. However, there is much promise beyond locked algorithms that is ripe for health care applications. These opportunities require careful oversight to ensure that the benefits of these advanced technologies outweigh the risks to patients. These machine learning algorithms can continually evolve and are often referred to as "adaptive" or "continuously learning" algorithms. Adaptive algorithms can learn from new user data presented to the algorithm through real-world use. The FDA is exploring a framework that would allow for modifications to algorithms to be made from real-world learning and adaptation, while ensuring that the safety and effectiveness of the software as a medical device is maintained [@B65].

Main challenges in the application of AI
========================================

At present, there are at least four limitations in AI technology that is based on machine learning, First, most machine learning methods have too few training sets and verification sets. More image data training is needed to further improve accuracy, sensitivity, and specificity. Transfer learning is an approach is more suitable when limited training data is available for the problem under consideration. In transfer learning, one can learn a complex model using data from a source domain where large-scale annotated images are available (e.g. natural images). Then, the model is further fine-tuned with data of the target domain where only a small number of annotated images are available (e.g. medical images) [@B66] (Fig [3](#F3){ref-type="fig"}).

The second limitation is that the examination/detection equipment used in different countries, regions, and medical institutions is not uniform; therefore, the acquired images have differences in quality and resolution, which will inevitably affect the accuracy of image analysis and thus affect the accuracy of the diagnosis. These differences will present certain obstacles in the wide-scale applications of AI technology. One solution to this problem is to unify and standardize the examination equipment. This will be difficult to achieve. Another method is to further improve AI machine learning methods at the framework and algorithm level so that they can be flexibly applied to images of different qualities while simultaneously ensuring the accuracy of intelligent diagnosis. This will increase the applicability of AI in different regions and medical institutions. However, a lot of research support is still needed in this area.

The third limitation is that the current machine learning methods for disease diagnosis lack "explanation capacity". They do not have the ability to provide the clinician or other users with the reason for the diagnosis. The output result is based only on training and intensive learning. Thus, it is only a simple statement based upon the differences in the patient and normal images. There is no explanation for why the differences exist or the pathological basis of the differences. This, along with other issues, will affect to some extent the acceptance of these devices by doctors in clinical applications and could even provoke confusion among clinicians.

Finally, the fourth limitation in machine learning-based AI technology is that the diagnosis of some rare diseases is still unreliable. Because of the scarcity of these diseases, there are not enough cases to meet the requirements of the training and verification sets. It is difficult or impossible to ensure the accuracy of the learning model in diagnosing rare diseases. To improve the diagnosis of rare diseases, it will be necessary to optimize machine learning algorithms. This can be done by transitioning from reliance on the number of learning samples for accuracy training to utilizing combinations of various training modes and types.

Suggestions for the application and development of AI in medicine
=================================================================

1. Consolidate the data foundation of AI applications {#Section1}
-----------------------------------------------------

AI must first collect a certain amount of data in the medical industry. The structure of current medical data is very complex, in part, because there is no uniformity in the standards for compilation, and this leads to widespread information islands. It is necessary to establish a mechanism for circulating and sharing medical data. Development of data desensitization methods will promote data standardization and normalization. These methods can be used to establish standard test data sets to consolidate the data foundations of AI applications.

2. Define the positioning of AI development {#Section2}
-------------------------------------------

In medicine, AI aims to help doctors (rather than substitute for doctors) to reduce the morbidity and mortality rates of patients waiting for professionals. Because doctors will not be replaced by AI, the diagnostic result of AI is only a reference for a clinical diagnosis, and doctors will always be responsible for the result. Currently, AI products in medicine play only an auxiliary role in the clinic, such as the diagnosis of DR, cancer screening, medical image recognition, disease rehabilitation, and in other fields.

3. Formulate regulations and laws for the application of AI in medicine {#Section3}
-----------------------------------------------------------------------

To achieve the uniform standards necessary for effective medical AI applications, laws, regulations, and other levels of governance must be established at the national level. The implementation of the national standards in industry and in routine and research clinical settings will ensure that the technology can be made widely and quickly available in the safest and most rational way. This will prudently promote the application of AI in the medical field.

4. Strengthen data security of AI data applications {#Section4}
---------------------------------------------------

As with the collection of any personal and medical data, the risk of inadvertent or pirated disclosure is a major concern. To reduce these risks, it is necessary to strengthen the construction of privacy protection, desensitize the data, and collect the data according to different levels and different granularities to reduce the risk of privacy disclosure. The United States has extensive experience in privacy protection of medical data. While enhancing privacy protection, it encourages the rational access and meaningful use of data and makes a selected portion of it available for research in real time, open access databases.

5. Promote the cultivation of interdisciplinary talents {#Section5}
-------------------------------------------------------

Future development of AI in medicine can be enhanced by focusing on the integration of disciplines such as medicine, information science, and engineering. This goal can be achieved by encouraging universities, research institutes, and enterprises to cooperate with each other, set up appropriate scholarships, and establish training bases and local pilot programs. Finally, an innovative talent introduction system and mechanism should be developed to attract highly talented students to carry out innovation and entrepreneurship in the field of medical AI, thus driving the further development of the field.

Future of AI application in clinic
==================================

Machine learning has shown its great potential in ophthalmology. Most of the current studies regarding intelligent diagnosis of eye diseases focus on dual classification problems, whereas many patients suffer from multiple categorical retinal diseases in the clinical setting. It is therefore necessary to have a model for detecting and distinguishing DR, AMD, glaucoma, and other retinal disorders simultaneously [@B67].

With a new generation of AI developed as a broad strategy, the applications of AI in the medical field will increase and improve. AI plays an important role in disease diagnosis and treatment, health management, drug research and development, precision medicine, etc. It can contribute significantly to solving problems of the uneven distribution of medical resources, reducing costs, and improving treatment efficiency. Applying AI helps to make up for the shortcomings of insufficient medical resources, enhance the fairness of medical services, and improve the construction of hierarchical diagnosis and treatment. In the future, AI will also offer important support for establishing an integrated medical service system. A qualified and efficient integrated medical service system can be built with the help of information-based systems.

Laws and regulations to define the legal status, responsibility sharing mechanisms, and supervision of automated systems are not yet enacted in China and most other countries. Given the complex ethical boundaries of medical AI application, the excessive control of medical AI will hinder innovation and development. On the other hand, the lack of management brings the risk of unclear subject responsibility in AI applications. Therefore, it is necessary to reasonably define AI in the medical field. The current laws on medical AI regulation are either non-existent or are in only the most primitive stages of development. There are no sound laws that regulate medical big data, the basis for medical AI. Further, there are no clear legal instructions regarding the ownership of AI data, the right to use it, privacy standards, data security, accountability norms, and whether laws can protect researchers, clinicians, and engineers from errors of innovation.

Summary
=======

Deep learning has the ability to probe more deeply into and discern more discriminative features from extremely large datasets. It has been applied in many research and clinical fields that rely on medical image analysis, making breakthrough progress in those disciplines. Due to unique features in ophthalmology, the diagnosis of eye diseases in clinical practice requires interpretation of many imaging studies for auxiliary diagnosis. However, detection resolution of the human eye is limited and so is human attention span. Proficiency levels of ophthalmologists also differ and it\'s inevitable for human errors to occur. As documented in the existing literature review, most of the current deep learning methods representing the leading level are the use of supervised learning, especially the CNN-based framework. Preliminary researches mainly focused on pre-training CNN and taking CNN as feature extractor. These pre-training networks could be downloaded directly, and conveniently applied to the analysis of any medical images. In recent two years, end-to-end training CNN has become a prioritized approach for the analysis of medical images. However, obtaining well-annotated data used for supervised learning is another major challenge for the application of deep learning to the analysis of medical images. As annotated data were usually limited at present, how to utilize unannotated images to achieve a high diagnostic accuracy using a combination of unsupervised and supervised learning will be another important development direction. In addition, electronic medical records (EMRs) contain a wealth of clinical diagnostic and treatment information that can be extracted and used to form diagnoses using natural language processing and deep learning. This information can be used to supplement the image data to formulate a complete diagnosis mimicking a human physician [@B68]. Thus, in the near foreseeable future, AI relying on deep learning will combine image analysis with EMRs, further advancing the diagnostic power and ability to monitor disease progression and response to treatment in ways never before anticipated.
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![Illustrations of transfer learning: a neural network is pretrained on ImageNet and subsequently trained on retinal, OCT, X-ray images, B-scans for different disease classifications](thnov09p7556g003){#F3}

###### 

Summary of publicly available databases of ocular retinal images

  Database                              Number of images   Camera Model                                                          Image Resolution (pixels)        Field of View   Application
  ------------------------------------- ------------------ --------------------------------------------------------------------- -------------------------------- --------------- -----------------------------------------------------------
  DRIVE [@B11]                          40                 Canon CR5                                                             768×584                          45°             Blood vessel segmentation
  STARE [@B12]                          400                Topcon trv-50                                                         605×700                          35°             Blood vessel segmentation; Optic disk detection
  Image-Ret [@B13],[@B14]                                                                                                                                                         
  DIARETDB0                             130                unknown                                                               1500×1152                        50°             Diabetic retinopathy detection
  DIARETDB1                             89                 unknown                                                               1500×1152                        50°             Diabetic retinopathy detection
  e-ophtha [@B15]                                                                                                                                                                 
  e-ophtha_EX                           82                 OPHDIAT Tele-medical network                                          2048×1360; 1440×960              \-              Diabetic retinopathy detection
  e-ophtha_MA                           381                                                                                      1440×960; 2544×1696                              Diabetic retinopathy detection
  HEI-MED [@B16]                        169                Zeiss Visucam PRO fundus camera                                       2196×1958                        45°             Hard exudate detection; Diabetic macular edema assessment
  Retinopathy Online Challenge [@B17]   100                Canon CR5-45-NM                                                       768×576; 1058×061; 1389×1383     45°             Microaneurysms detection
  Messidor [@B18]                       1200               TopCon TRC NW6                                                        1440×960; 2240×1488; 2304×1536   45°             Diabetic retinopathy detection
  RIM-ONE [@B19]                        169                Nidek AFC-210 with a body of a Canon EOS 5D                           2144 × 1424                      \-              Optic nerve head segmentation
  DRIONS-DB [@B20]                      110                Color analogue fundus camera digitized by HP-PhotoSmart-S20 scanner   600×400                          \-              Optic nerve head segmentation

###### 

Summary of influential papers on ophthalmic image analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease       Procedures / examinations              Data sets                                                                                                                                             Deep learning techniques                                                                                 Performance                                                                                                                                                                                         Reference                   
  ------------- -------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- --
  Keratoconus   Pentacam                               194 normal, 454 keratoconus, 67 forme fruste, 28 astigmatic, 117 after refractive surgery                                                             SVM                                                                                                      Acc: 98.9%; Sen: 99.1%; Spe: 98.5%; AUC:0.99                                                                                                                                                        Hidalgo et al. [@B37]       

                Dual Scheimpflug Analyzer              177 normal, 148 keratoconus                                                                                                                           Decision Tree                                                                                            Sen: 100%; Spe: 99.5%                                                                                                                                                                               Smadja et al. [@B38]        

                Pentacam HR                            30 normal, 15 unilateral keratoconus, 30 bilateral keratoconus                                                                                        FNN                                                                                                      Bilateral keratoconus versus normal; AUC: 0.99; Sen: 100%; Spe: 95%                                                                                                                                 Kovacs et al. [@B39]        

  Pterygium     Anterior segment photographed images   2,692 non-pterygium, 325 pterygium                                                                                                                    Shape features + SVM/ANN                                                                                 Acc: 91.27%; AUC: 0.956; Sen: 88.7%; Spe: 88.3%                                                                                                                                                     Zaki et al. [@B40]          

  Cataract      Slit-lamp image                        5,378 images with decimal grading scores ranging from 0.1 to 5.0.                                                                                     CRNN                                                                                                     70.7% exact integral agreement ratio (R0); 88.4% decimal grading error ≤ 0.5 (Re0.5); 99.0% decimal grading error ≤ 1.0 (Re1.0 ).                                                                   Gao et al. [@B41]           

                Slit-lamp image                        476 normal, 410 cataract                                                                                                                              DCNN                                                                                                     Cataract vs Normal:\                                                                                                                                                                                Long et al. [@B34]          
                                                                                                                                                                                                                                                                                                                      Acc:98.87%;Sen:98.78%\                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                      Spe:98.95%                                                                                                                                                                                                                      

                Fundus image                           767 normal, 472 cataract (246 mild cataract,128 moderate cataract, and 98 severe cataract)                                                            SVM, BPNN                                                                                                Acc: 93.2% for detection,84.5% for grading; Sen:94.2% for detection,74.6-89.3% for grading;\                                                                                                        Yang et al. [@B42]          
                                                                                                                                                                                                                                                                                                                      Spe:91.5% for detection,90.4-98.9% for grading                                                                                                                                                                                  

                Slit-lamp image                        476 normal, 410 pediatric cataract                                                                                                                    CNN, SVM                                                                                                 Acc, Sen, and Spe: classification (97.07%, 97.28%, and 96.83%,) three-degree grading area (89.02%, 86.63%, and 90.75%) density (92.68%, 91.05%, and 93.94%) location (89.28%, 82.70%, and 93.08%)   Liu et al. [@B43]           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  POAG          Fundus image                           Training set:125,189; Validation set: 71,896                                                                                                          DLS                                                                                                      AUC: 0.942; Sen: 96.4%; Spe: 87.2%                                                                                                                                                                  Ting et al. [@B26]          

                Fundus image                           Training set: 31,745; Validation set: 8,000                                                                                                           DCNN                                                                                                     AUC: 0.98; Acc: 92.9%; Sen: 95.6%; Spe: 92.0%; AUC: 0.986                                                                                                                                           Li et al. [@B29]            

                Fundus image                           589 normal, 837 glaucoma                                                                                                                              CNN                                                                                                      Acc: 98.13%; Sen: 98%; Spe: 98.3%                                                                                                                                                                   Raghavendra et al. [@B44]   

                Fundus image                           30 normal, 30 open-angle glaucoma                                                                                                                     SVW                                                                                                      Acc:91.67; Sen:90%;Spe:93.33%                                                                                                                                                                       Krishnan et al. [@B45]      

                Visual field                           Training set:257; Test set: 129                                                                                                                       ANN                                                                                                      AUC: 0.890; Sen: 78.3%; Spe: 89.5%                                                                                                                                                                  Oh et al. [@B46]            

                Fundus image                           266 normal, 72 mild, 86 moderate, 86 severe glaucoma                                                                                                  SVM                                                                                                      Acc: 93.1%; Sen: 89.75%; Spe: 96.2%                                                                                                                                                                 Acharya et al. [@B47]       

                Fundus image and SLO image             Normal/glaucoma Fundus images:85/39; Normal/glaucoma SLO images: 46/19                                                                                RIFM                                                                                                     Acc for Fundus images: 94.4%,SLO images: 93.9%;Sen for Fundus images: 92.3%,SLO images: 89.5%;Spe for Fundus images: 95.3%,SLO images: 93.5%                                                        Haleem et al. [@B48]        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                Visual fields                          53 glaucoma eyes, 108 normal eyes                                                                                                                     FNN                                                                                                      AUC: 92.6%, The sensitivity was 77.8%,54.6%, and 50.0%, respectively, at the specificity of 90%, 95%,and 99%                                                                                        Asaoka et al. [@B31]        

  DR            Fundus image                           Training set:76,370; Validation set: 112,648                                                                                                          DLS                                                                                                      For referable DR: AUC: 0.936; Sen: 90.5; Spe: 91.6%; For vision-threatening DR: AUC: 0.958; Sen: 100%; Spe: 91.1%                                                                                   Ting et al. [@B26]          

                Fundus image                           Development Data Set (EyePACS in the United States and 3 eye hospitals in India): 128,175 Validation Data Set (EyePACS-1: 9,963; Messidor-2: 1,748)   DCNN                                                                                                     AUC: 0.991 for EyePACS,0.990 for Messidor;Sen: 90.3% for EyePACS,87% for Messidor;Spe: 98.1% for EyePACS,98.5% for Messidor                                                                         Gulshan et al. [@B4]        

                Fundus image                           170 DR, 170 normal                                                                                                                                    PNN-GA, SVM quadratic kernels                                                                            PNN-GA: Acc:99.41%,Sen:99.41%\                                                                                                                                                                      Ganesan et al. [@B49]       
                                                                                                                                                                                                                                                                                                                      Spe:99.41%; SVM: Acc:99.12 % Sen:98.82%,Spe:99.41%                                                                                                                                                                              

                Fundus image                           EyePACS: 75,137 DR images; External validation: MESSIDOR 2 and E-Ophtha                                                                               DCNN                                                                                                     AUC 0.94 for Messidor 2, 0.95 for E-Ophtha;Sen 93% for Messidor 2,87% for E-Ophtha;Spe 90% for Messidor 2,94% for E-Ophtha                                                                          Gargeya et al. [@B50]       

                Fundus image                           Training set: 327 diabetic patients; Validation set: 725 diabetic patients                                                                            LASSO                                                                                                    Acc: 89.2%; AUC: 0.90; Sen: 75%; Spe: 89.6%                                                                                                                                                         Oh et al. [@B51]            

                Fundus image                           Training set: 400; Testing set: 9,954                                                                                                                 Ensemble of classifiers with hidden Markov chain for context information, trained by genetic algorithm   Sen: 92.2%; Spe: 90.4%                                                                                                                                                                              Tang et al. [@B52]          

                Fundus image                           Messidor-2 dataset: 1,748                                                                                                                             CNN                                                                                                      Referable DR: AUC: 0.980; Sen: 96.8%; Spe: 87%; Vision threatening DR: AUC: 0.989; Sen: 100%; Spe: 90.8%                                                                                            Abramoff et al. [@B53]      

                Fundus image                           4,445 DR; 5,494 normal                                                                                                                                DCNN                                                                                                     Acc: 0.81                                                                                                                                                                                           Takahashi et al. [@B54]     

                Fundus image                           DIARETDB1, FAZ, MESSIDOR, Private dataset: 750 (Normal: 150, mild NPDR: 150, moderate NPDR: 150, severe NPDR: 150, PDR: 150)                          DNN                                                                                                      AUC: 0.924; Sen: 92.18%; Spe: 94.50%                                                                                                                                                                Abbas et al. [@B55]         

  DME           SD-OCT                                 Training set: 11,349; DEM; 51,140 normal; Validation set: 250 DME, 250 normal                                                                         CNN                                                                                                      Acc: 98.2%; Sen: 96.8%; Spe: 99.6%                                                                                                                                                                  Kermany et al. [@B27]       

  DME           Fundus image                           283 DR; 1,086 normal                                                                                                                                  Ensemble of Gaussian mixture model and SVM with RBF kernel                                               Acc: 96.8%; Sen: 97.3%; Spe: 95.9%                                                                                                                                                                  Akram et al. [@B56]         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  AMD           Fundus image                           Training set 72,610; Validation set: 35,948                                                                                                           DLS                                                                                                      AUC: 0.931; Sen: 93.2%; Spe: 88.7%                                                                                                                                                                  Ting et al. [@B26]          

                Fundus image                           AREDS dataset: \>130,000                                                                                                                              DCNN                                                                                                     AUC: 0.94∼0.96 Acc: 88.4%∼91.6% Sen: 71%∼88.4% Spe: 91.4%∼94.1%                                                                                                                                     Burlina et al. [@B57]       

                Fundus image                           AREDS dataset: 5,664                                                                                                                                  DCNN                                                                                                     Acc 79.4% (4-class) 81.5% (3-class); 93.4% (2-class)                                                                                                                                                Burlina et al. [@B58]       

                SD-OCT                                 Training and validation sets: 1,012 (AMD: 701; normal: 311); Test:100 (AMD: 50, normal: 50)                                                           DCNN                                                                                                     Acc: 96%; Sen: 100%; Spe: 92%                                                                                                                                                                       Treder et al. [@B59]        

                Fundus image                           135 AMD subjects, 135 normal subjects                                                                                                                 Feature extracted by Discrete wavelet transform and others for feature selection and classification      Average Acc: 93.7%; Sen: 91.11%; Spe: 96.3%                                                                                                                                                         Mookiah et al. [@B60]       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                OCT                                    48,312 AMD; 52,690 normal                                                                                                                             DCNN                                                                                                     AUC: 0.975; Sen: 92.6%; Spe: 93.7%                                                                                                                                                                  Lee et al. [@B61]           

                SD-OCT                                 1,289                                                                                                                                                 CNN                                                                                                      The mean Dice coefficient for human interrater reliability and deep learning were 0.750 and 0.729, respectively.                                                                                    Lee et al. [@B62]           

  CNV           SD-OCT                                 Training set: 37,206 CNV, 51,140 normal; Validation set: 250 CNV, 250 normal                                                                          CNN                                                                                                      Acc: 100%; Sen:100%; Spe:100%                                                                                                                                                                       Kermany et al. [@B27]       

  CNV           Fluorescein angiography                33                                                                                                                                                    AdaBoost                                                                                                 Accuracy: 83.26%                                                                                                                                                                                    Tsai et al. [@B63]          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RBFNN, radial basis function neural network; SVM, support vector machine; MLP, multi-layer perceptron; CRNN, convolutional-recursive neural networks; DCNN, Deep-learning convolutional neural network; BPNN, Back propagation neural network; DLS, deep learning system; CNN-FE, convolutional neural networks feature-exaggerated; MLP-BP, Multilayer Perceptron with Back Propagation; RIFM, Regional Image Features Model; FNN, feed-forward neural network; PNN-GA, probabilistic neural network-genetic algorithms; LASSO, least absolute shrinkage and selection operator; NB, naive Bayes; PNN, probabilistic neural network; RBF, Radial basis function; SD-OCT, spectral domain optical coherence tomography; SLO, Scanning Laser Ophthalmoscopy. Acc, accuracy; Sen, sensitivity; Spe, specificity; Vs, versus; AUC, area under the curve; POAG, primary open-angle glaucoma; AMD, age-related macular degeneration; OCT, optical coherence tomography; DR, diabetic retinopathy.
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